Aktis Oncology Upsizes IPO to Raise $317.7 Million in U.S.

Aktis Oncology, a prominent player in the cancer drug development sector, has announced its decision to upsize its initial public offering (IPO) to raise $317.7 million in the U.S. market. This significant move, announced on January 7, 2026, underscores the growing investor interest in the biotech and oncology space. The upsizing of the IPO indicates a robust demand from investors, reflecting confidence in the company's potential within the oncology sector.

The decision to increase the size of the offering highlights the critical role that public equity markets play in funding innovation and growth in the biotech industry. By seeking to raise substantial capital through the IPO, Aktis Oncology aims to leverage public market access to support its ongoing development efforts in cancer treatment.